| 1st Nov 2018 3:00 pm |
RNS |
Total Voting Rights |
| 31st Oct 2018 9:45 am |
RNS |
Additional financial information-Grünenthal deal |
| 30th Oct 2018 7:00 am |
RNS |
Grünenthal Agreement for rights to Nexium, Vimovo |
| 23rd Oct 2018 7:00 am |
RNS |
AstraZeneca Extends Innate Pharma Collaboration |
| 22nd Oct 2018 7:00 am |
RNS |
Lynparza shows 70% reduction in PFS ovarian cancer |
| 19th Oct 2018 1:09 pm |
RNS |
CHMP positive opinion Bevespi Aerosphere |
| 16th Oct 2018 7:00 am |
RNS |
FDA Orphan Drug for Lynparza in pancreatic cancer |
| 1st Oct 2018 3:00 pm |
RNS |
Total Voting Rights |
| 1st Oct 2018 7:00 am |
RNS |
Atacand Agreement with Cheplapharm Completed |
| 28th Sep 2018 4:00 pm |
RNS |
Previous Announcement Regarding Appointment Of NED |
| 25th Sep 2018 1:15 pm |
RNS |
Overall survival data for Imfinzi: Stage III NSCLC |
| 24th Sep 2018 4:10 pm |
RNS |
EMA approves AZ's Imfinzi for Stage III NSCLC |
| 24th Sep 2018 7:00 am |
RNS |
Farxiga gets positive result in DECLARE-TIMI 58 |
| 14th Sep 2018 7:00 am |
RNS |
FDA approves AZ's Lumoxiti in hairy cell leukaemia |
| 7th Sep 2018 7:00 am |
RNS |
Tezepelumab FDA Breakthrough Therapy Designation |
| 6th Sep 2018 7:00 am |
RNS |
Directorate Change |
| 3rd Sep 2018 3:00 pm |
RNS |
Total Voting Rights |
| 31st Aug 2018 7:00 am |
RNS |
AstraZeneca Update on Anifrolumab in SLE |
| 30th Aug 2018 7:00 am |
RNS |
EC approves Bydureon BCise device for T2 diabetes |
| 23rd Aug 2018 7:00 am |
RNS |
AstraZeneca PIIIb trial update for Bevespi in COPD |
| 21st Aug 2018 7:00 am |
RNS |
AZ's Tagrisso approved in Japan for 1st-line NSCLC |
| 15th Aug 2018 7:00 am |
RNS |
AstraZeneca prices a $3bn bond issue |
| 3rd Aug 2018 7:00 am |
RNS |
EMA grants OD for selumetinib in NF1 |
| 1st Aug 2018 3:00 pm |
RNS |
Total Voting Rights |
| 27th Jul 2018 2:00 pm |
RNS |
CHMP recommends Imfinzi for Stage III nsclc |
| 26th Jul 2018 7:00 am |
RNS |
AZN: H1 2018 Results |
| 24th Jul 2018 7:00 am |
RNS |
Atacand to be divested to Cheplapharm in Europe |
| 18th Jul 2018 4:11 pm |
RNS |
Holding(s) in Company |
| 18th Jul 2018 12:00 pm |
RNS |
Holding(s) in Company |
| 2nd Jul 2018 3:00 pm |
RNS |
Total Voting Rights |
| 2nd Jul 2018 7:00 am |
RNS |
Imfinzi approved in Japan for Stage III nsclc |
| 2nd Jul 2018 7:00 am |
RNS |
Lynparza approved in Japan for BRCAm breast cancer |
| 29th Jun 2018 3:00 pm |
RNS |
Bydureon receives positive CHMP opinion for BCise |
| 28th Jun 2018 1:30 pm |
RNS |
AZ and Luye Pharma complete agreement for Seroquel |
| 27th Jun 2018 7:00 am |
RNS |
Lynparza: significant PFS 1st-line ovarian cancer |
| 26th Jun 2018 7:00 am |
RNS |
Board Committee Changes |
| 22nd Jun 2018 7:00 am |
RNS |
Publication of a Prospectus |
| 12th Jun 2018 7:00 am |
RNS |
Update: lanabecestat Phase III Alzheimer's trials |
| 8th Jun 2018 5:30 pm |
RNS |
EU APPROVES TAGRISSO FOR 1ST-LINE NSCLC |
| 8th Jun 2018 7:00 am |
RNS |
Director Declaration |
